<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30161">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714062</url>
  </required_header>
  <id_info>
    <org_study_id>OB-402</org_study_id>
    <nct_id>NCT02714062</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to describe the pharmacokinetic profiles of VI-0521
      in obese adolescents.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apparent clearance (CL/F) of phentermine and topiramate</measure>
    <time_frame>On Days 14, 28, 42, and 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vc/F) of phentermine and topiramate</measure>
    <time_frame>On Days 14, 28, 42, and 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) of phentermine and topiramate</measure>
    <time_frame>On Days 14, 28, 42, and 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration (Cmax) of phentermine and topiramate</measure>
    <time_frame>On Days 14, 28, 42, and 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in body weight</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in waist circumference</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in blood pressure</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in absolute value of glycemic parameters (fasting glucose, insulin, HOMA-IR)</measure>
    <time_frame>56 days</time_frame>
    <description>OGTT of fasting and 2-hr glucose and insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in lipid parameters (triglyceride &amp; HDL)</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visual analog scale (VAS) hunger scores</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visual analog scale (VAS) satiety scores</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Pediatric Obesity</condition>
  <condition>Childhood Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VI-0521 Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VI-0521 Top Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, po once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VI-0521 Mid Dose</intervention_name>
    <description>phentermine 7.5 mg and topiramate 46 mg, po once daily</description>
    <arm_group_label>VI-0521 Mid Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VI-0521 Top Dose</intervention_name>
    <description>phentermine 15 mg and topiramate 92 mg, po once daily</description>
    <arm_group_label>VI-0521 Top Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent

          -  Provide written assent (of study subject);

          -  Adolescent ≥12 and &lt;18 years of age;

          -  Have a BMI ≥ the 95th percentile of BMI for age and gender;

          -  Female subjects must be using adequate contraception;

          -  Willing and able to comply with all study requirements

        Exclusion Criteria:

          -  Condition or disease interfering with metabolism;

          -  Any medical treatment with insulin;

          -  Hyperthyroidism, or clinically significant hypothyroidism;

          -  Any history of bipolar disorder or psychosis, major depressive disorder, or history
             of suicidal behavior or ideation, or any use of antidepressant medications;

          -  Use of chronic systemic glucocorticoid or steroid therapy;

          -  History of any eating disorders;

          -  Any history of laxative abuse;

          -  Prior bariatric surgery;

          -  Any history of nephrolithiasis;

          -  Any history of epilepsy, or treatment with anti-seizure medications;

          -  Positive urine drug screen;

          -  Current smoker or smoking cessation within the previous 3 months of screening;

          -  Obesity of a known genetic or endocrine origin;

          -  Treatment with any over-the-counter or prescription weight loss drug, or
             attention-deficit/hyperactivity disorder (ADHD);

          -  Allergy or hypersensitivity to phentermine or topiramate or history of anaphylaxis to
             any drug;

          -  Use of any investigational medication or device for any indication or participation
             in a clinical study within 30 days prior to screening; or

          -  Any medical or surgical condition which would impair the ability of the subject to
             complete the study, compromise the quality of study data, or pose an unacceptable
             risk to the safety of the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 30, 2016</lastchanged_date>
  <firstreceived_date>March 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adolescent Obesity</keyword>
  <keyword>Childhood Obesity</keyword>
  <keyword>Qsymia</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>VI-0521</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
